Division of Gastroenterology, University of California, San Diego, 92103, USA.
Clin Liver Dis. 2012 May;16(2):347-69. doi: 10.1016/j.cld.2012.03.003.
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to better define various phases of infection, describes the use of HBV core, precore, and viral genotyping as well as host IL28B genotyping to predict response to interferon therapy, and reports on the management of HBV in 3 special populations (pregnancy, postliver transplantation, and in the setting of chemotherapy or immunosuppression).
慢性乙型肝炎病毒 (HBV) 感染的管理需要了解疾病的自然史以及治疗选择的风险、益处和局限性。本文涵盖了何时开始抗病毒治疗的原则,讨论了使用乙型肝炎表面抗原定量来更好地定义感染各阶段的最新进展,描述了乙型肝炎核心、前核心和病毒基因分型以及宿主 IL28B 基因分型在预测干扰素治疗反应中的应用,并报告了乙型肝炎在 3 个特殊人群(妊娠、肝移植后以及化疗或免疫抑制环境)中的管理。